Skip to main content
[Preprint]. 2023 Sep 11:rs.3.rs-2248327. Originally published 2022 Dec 2. [Version 2] doi: 10.21203/rs.3.rs-2248327/v2

Figure 3. Screening of the SARS-CoV-2 potential variants (PVs) for binding to Fc-ACE2 using yeast display.

Figure 3.

(A) The RBDs of the PVs were expressed on the surface of Saccharomyces cerevisiae cells as genetic fusions to the AGA2 surface protein. An anti-Myc antibody (Ab) and an anti-human secondary Ab labeled with different fluorophores were subsequently used to label the RBD-expressing cells and the cells bound to Fc-ACE2, respectively. (B) Saccharomyces cerevisiae cells displaying the indicated RBD PV were incubated with 40 nM Fc-ACE2. Binding to Fc-ACE2 was detected with an Alexa647-conjugated anti-human secondary Ab. The RBD variants highlighted with red arrows were chosen for further experimental characterization.